REDWOOD CITY, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. , today announced two presentations regarding its oncology product candidate glufosfamide. The presentations will take place at the 2007 European Cancer Conference (ECCO) being held September 23 to 27, 2007, at the International Conference Center in Barcelona, Spain.
As announced on February 26, 2007, the Phase 3 trial of glufosfamide showed that the overall survival in patients with metastatic pancreatic cancer who had relapsed after gemcitabine chemotherapy was 18% higher in the glufosfamide arm compared to those who received best supportive care (BSC), but the result did not reach statistical significance. Detailed analysis of the data from that study suggests that glufosfamide is active in certain subgroups of patients. The Company believes that additional clinical investigation of these subgroups is warranted. These data and subgroups will be described during the oral presentation on September 27.
The following oral presentation will take place:
Glufosfamide (GLU) in metastatic pancreatic adenocarcinoma previously treated with gemcitabine: Results of a Phase 3 trial.
Gastrointestinal malignancies -- noncolorectal cancer, Room 111 Thursday, September 27, 2007 at 10:15am
As announced on December 27, 2006, the response rate for the Phase 2 glufosfamide plus gemcitabine front-line pancreatic cancer trial was 21% (including one unconfirmed partial response). The detailed results of the Phase 2 trial, including complete 12-month survival data, will be presented during a poster presentation on September 26.
The following poster presentation will take place:
Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: Results of a Phase 2 trial.
Gastrointestinal malignancies -- noncolorectal cancer, Level 0 Wednesday, September 26, 2007 from 9:00am to 12:00pm
A copy of the Phase 3 abstract will be available on the Threshold website on September 27. A copy of the Phase 2 poster and abstract will be available on the website on September 26 at http://investor.thresholdpharm.com/calendar.cfm.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company’s drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional
information, please visit our website (http://www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold’s product candidates, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold’s ability to commence its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading “Risk Factors” in Threshold’s Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on August 7, 2007 and is available from the SEC’s website (http://www.sec.gov) and on our website (http://www.thresholdpharm.com) under the heading “Investors.” We do not intend to update any forward-looking statement made in this news release.
Contact: Denise T. Powell Sr. Director, Corporate Communications Threshold Pharmaceuticals, Inc. 650-474-8206, dpowell@thresholdpharm.com
Threshold Pharmaceuticals, Inc.
CONTACT: Denise T. Powell, Sr. Director, Corporate Communications ofThreshold Pharmaceuticals, Inc., +1-650-474-8206,dpowell@thresholdpharm.com
Web site: http://www.thresholdpharm.com/
